City of Hope and UC Berkeley Scientists Develop AI-Driven Platform to Assess Breast Cancer Risk via Cellular Mechanics Scientists at City of Hope and the University of California, Berkeley, have developed a groundbreaking microfluidic platform that uses artificial intelligence to assess breast cancer risk by analyzing the mechanical properties of single breast epithelial cells. The innovation, published in The Lancet’s eBioMedicine, introduces a novel method to evaluate cellular aging and stress resilience, offering a direct biophysical measure of cancer susceptibility. This technology marks a significant departure from traditional risk assessment tools, which have historically relied on genetic factors and indirect methods like mammographic breast density. The platform applies mechanical stress to individual cells by squeezing them through narrow microfluidic channels, mimicking biomechanical stressors. By measuring how quickly cells deform and recover their shape, researchers can quantify their "mechanical age"—a concept borrowed from material engineering that assesses wear and fatigue in metals and polymers. This approach reveals subtle differences in cellular behavior that correlate with heightened cancer risk, even in individuals without known genetic predispositions. For example, some younger women’s cells exhibited stiffness and prolonged recovery times, indicating advanced mechanical aging despite their chronological age. Traditional methods, such as genetic testing for mutations like BRCA1/BRCA2, account for only about 6% of breast cancer cases. For the remaining 94%, risk stratification has been imprecise, often leading to over-diagnosis or missed early warnings. The MechanoAge platform addresses this gap by providing a direct, cell-level assessment.#national_institutes_of_health #university_of_california_berkeley #city_of_hope #the_lancet_ebmedicine #mechanoage
Why Palantir Stock Just Popped Palantir Technologies (NASDAQ: PLTR) stock surged 5% by 9:45 a.m. ET on Monday after Wedbush analyst Dan Ives reaffirmed his outperform rating for the company. Ives remains confident the stock will reach $230 within a year, which would represent a 45% gain from its current price. The analyst’s optimism is rooted in Palantir’s position as a government IT contractor specializing in artificial intelligence, with clients including the Department of Defense, the National Institutes of Health, the Centers for Disease Control and Prevention, and international defense ministries, healthcare systems, and law enforcement agencies. Ives argues that Palantir is strategically aligned with the government’s highest-priority projects, positioning it to benefit from accelerated growth in well-funded programs. Despite recent investor concerns about the AI industry’s health, Ives believes Palantir can overcome these challenges. The stock has declined over 23% since hitting an all-time high in early November but is still up 56% over the past 52 weeks. Analysts predict the company will grow earnings by 47% annually over the next five years, though its current valuation remains high. With a market capitalization of $360 billion, Palantir trades at 239 times trailing earnings, raising questions about whether its stock has already priced in future growth. The Motley Fool’s Stock Advisor team recently highlighted Palantir as one of the top stocks to avoid, citing its elevated valuation. The team’s recommendations have historically delivered strong returns, with past examples like Netflix and Nvidia generating significant gains for investors who followed their advice.#palantir_technologies #dan_ives #department_of_defense #national_institutes_of_health #centers_for_disease_control_and_prevention
